Nanoform and Orion collaborate on 'nanoformed' APIs
Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.
Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, have announced a collaboration to apply the former's Controlled Expansion of Supercritical Solutions (CESS) technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development.
Many new chemical entities struggle to progress into clinical development due to their physico-chemical properties and respective solubility and bioavailability challenges. This issue is expected to exacerbate as molecular complexity increases in drug discovery.
Nanoform's CESS technology produces nanoformed "designed-for-purpose" API particles, as small as 10 nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability.
This collaboration with Nanoform presents an opportunity to enhance Orion's formulation process and provide poorly soluble molecules with a path to clinical trials.
Dr Juha Kiesvaara, VP Global Pharmaceutical Research at Orion Corporation, believes that using nanoparticles in the range that Nanoform can produce will provide them with a "great opportunity" to simplify the formulation process, develop optimal products and enable poorly soluble molecules to progress into clinic.
"Producing tailored nanoparticles smaller than 200 nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is challenging to do by current pharmaceutical manufacturing techniques or processes. Now that Nanoform has a path to clinical development with their upcoming GMP facility we are excited to see how they can add value to Orion's drug development products," said Dr Juha Kiesvaara.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance